- Home
- IGMS vs RILY Comparison
IGMS vs RILY Comparison
Compare IGMS & RILY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- RILY
- Stock Information
- Founded
- IGMS 1993
- RILY 1973
- Country
- IGMS United States
- RILY United States
- Employees
- IGMS N/A
- RILY N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- RILY Investment Managers
- Sector
- IGMS Health Care
- RILY Finance
- Exchange
- IGMS Nasdaq
- RILY Nasdaq
- Market Cap
- IGMS 81.9M
- RILY 91.8M
- IPO Year
- IGMS 2019
- RILY 2007
- Fundamental
- Price
- IGMS $1.27
- RILY $5.58
- Analyst Decision
- IGMS Hold
- RILY
- Analyst Count
- IGMS 8
- RILY 0
- Target Price
- IGMS $6.00
- RILY N/A
- AVG Volume (30 Days)
- IGMS 1.3M
- RILY 1.8M
- Earning Date
- IGMS 08-13-2025
- RILY 08-14-2025
- Dividend Yield
- IGMS N/A
- RILY N/A
- EPS Growth
- IGMS N/A
- RILY N/A
- EPS
- IGMS N/A
- RILY N/A
- Revenue
- IGMS $2,681,000.00
- RILY $854,383,000.00
- Revenue This Year
- IGMS $252.44
- RILY N/A
- Revenue Next Year
- IGMS $46.48
- RILY N/A
- P/E Ratio
- IGMS N/A
- RILY N/A
- Revenue Growth
- IGMS 27.36
- RILY N/A
- 52 Week Low
- IGMS $0.92
- RILY $2.67
- 52 Week High
- IGMS $22.50
- RILY $20.36
- Technical
- Relative Strength Index (RSI)
- IGMS 48.73
- RILY 65.70
- Support Level
- IGMS $1.26
- RILY $5.27
- Resistance Level
- IGMS $1.37
- RILY $6.33
- Average True Range (ATR)
- IGMS 0.03
- RILY 0.70
- MACD
- IGMS -0.01
- RILY 0.12
- Stochastic Oscillator
- IGMS 8.33
- RILY 74.35
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About RILY B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.